NFKB1 and cholangiocarcinoma: It was further shown that inhibiting the action of NF-κB using DHMEQ (dehydroxymethylepoxyquinomicin), a novel NF-κB inhibitor, could effectively suppress growth of CCA cell lines and CCA in inoculated mice.